Skip to main content
. 2013 Jan 21;98(2):E346–E354. doi: 10.1210/jc.2012-3343

Table 3.

Glucocorticoid and Mineralocorticoid Treatment

Mutation Group
Significance of Mutation Group (ANOVA) Significance of Tukey's Paired Comparisons
Null A B C Null vs A Null vs B Null vs C A vs B A vs C B vs C
Hydrocortisone only
    n (%) 10 (29.4%) 10 (23.8%) 9 (25.0%) 7 (20.6%) .864
    Median dose (range), mg/d 30 (15–30) 25 (15–30) 30 (20–33) 20 (10–35) .021a .178 1.000 .023a 1.000 1.000 .343
    Median dose per BSA (range), mg/m2 · d 17.3 (8.1–30.8) 14.3 (7.9–16.8) 15.7 (10.7–20.3) 11.1 (4.5–20.8) .043a .321 1.000 .053 1.000 1.000 .375
Prednisolone only
    n (%) 12 (35.3%) 15 (35.7%) 16 (44.4%) 17 (50.0%) .529
    Median dose (range), mg/d 6.8 (5–9) 7.5 (4–10) 5.5 (3–10) 5 (1–8) .124
    Median dose per BSA (range), mg/m2 · d 3.7 (2.6–4.9) 3.5 (1.9–6.0) 3.2 (1.2–4.9) 3.0 (0.4–4.5) .324
Dexamethasone only
    n (%) 6 (17.6%) 11 (26.2%) 10 (27.8%) 6 (17.6%) .629
    Median dose (range), mg/d 0.50 (0.25–0.75) 0.50 (0.25–0.75) 0.35 (0.25–0.75) 0.25 (0.25–0.50) .176
    Median dose per BSA (range), mg/m2 · d 0.30 (0.13–0.49) 0.24 (0.11–0.47) 0.21 (0.13–0.46) 0.14 (0.11–0.25) .246
Combination of glucocorticoids, n (%) 6 (17.6%) 6 (14.3%) 1 (2.8%) 3 (8.8%) .171
Reverse circadian glucocorticoid administration, n (%) 17 (50.0%) 19 (45.2%) 17 (47.2%) 14 (41.2%) .914
Fludrocortisone
    n (%) 32 (94.1%) 33 (78.6%) 14 (38.9%) 10 (29.4%) <.001a .098 <.001b <.001b <.001b <.001b .457
    Median dose (range), μg/d 163 (100–500) 100 (50–200) 100 (50–200) 100 (50–500) .015a .134 .044a .155 1.000 1.000 1.000
    Median dose per BSA (range), μg/m2 · d 94 (51–231) 64 (27–134) 63 (30–121) 57 (27–219) .016a .058 .270 .074 1.000 1.000 1.000
a

Significant at the 5% level.

b

Significant at the Bonferroni-adjusted level of 1.67%.